Yellow Fever

Novel Technologies for Vaccine Development

“…As exemplified by yellow fever 17D vaccine, in YF endemic areas, a vaccinated child is fully protected over a 50-year lifetime against different genotypes of YF for an investment of a few cents per year (Galbraith and Barrett 2009;Monath 2005). As exemplified by yellow fever 17D vaccine, in YF endemic areas, a vaccinated child is fully protected over a 50-year lifetime against different genotypes of YF for an investment of a few cents per year (Galbraith and Barrett 2009;Monath 2005).…”

Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs

“…In YF endemic areas a vaccinated child is fully protected over a 50-year life time against different genotypes of YF for an investment of a few cents per year [1, 2]. Since 1937 more than 540 million doses have been delivered world-wide and no reversion to wild-type YF virus has been reported.…”

“…The introduction of active immunization programs and vector control measures in 1937–1938, transformed YF from a major human plague to a medical curiosity by the end of World War II [1, 16, 17]. However, during the past 20 years the absence of effective public health policy, social-ecological factors and vaccine shortage resulted in a resurgence of YF (~ 200,000 cases and 30,000 deaths annually) in South America and Africa.…”

“…Thirty-two African countries with a total population of 610 million people including more than 219 million urbanites are now considered at risk for YF. The vast majority of cases and deaths take place in sub-Saharan Africa, where YF is a major public health problem occurring in epidemic patterns [1]. In 2007 WHO–UNICEF recommended including YF17D vaccine in routine infant immunization programs and initiated mass vaccination campaigns to rapidly increase population immunity in high-risk areas [18].…”